ESSA Historical Financial Ratios

EPIX Stock

USD 1.68 0.02 1.18%

ESSA Pharma is recently reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 52.01 or Days Sales Outstanding of 21.4 K will help investors to properly organize and evaluate ESSA Pharma financial condition quickly.

Quick Ratio Current Ratio

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

About ESSA Financial Ratios Analysis

ESSA PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate ESSA Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ESSA financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across ESSA Pharma history.

ESSA Pharma Financial Ratios Chart

At this time, ESSA Pharma's Tangible Book Value Per Share is fairly stable compared to the past year. Graham Number is likely to rise to 12.85 in 2025, whereas Free Cash Flow Yield is likely to drop (0.03) in 2025.

Price To Sales Ratio Days Sales Outstanding Invested Capital Average Payables

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing ESSA Pharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on ESSA Pharma sales, a figure that is much harder to manipulate than other ESSA Pharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Invested Capital

Invested capital represents the total cash investment that shareholders and debt holders have contributed to ESSA Pharma. There are two different methods for calculating ESSA Pharma invested capital: operating approach and financing approach. Understanding ESSA Pharma invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Most ratios from ESSA Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.At this time, ESSA Pharma's Tangible Book Value Per Share is fairly stable compared to the past year. Graham Number is likely to rise to 12.85 in 2025, whereas Free Cash Flow Yield is likely to drop (0.03) in 2025.

	2024	2025 (projected)
Net Current Asset Value	770.5	684.89
Days Payables Outstanding	7.2K	8.1K

Net Current Asset Value Days Payables Outstanding

ESSA Pharma fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Invested Capital	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Net Current Asset Value	Income Quality
Price To Sales Ratio		-0.16	1.0	0.06	-0.18	1.0	-0.06	0.02	0.24	-0.16	1.0	-0.06	-0.31	-0.05	-0.43	0.01	-0.37	1.0	0.35	-0.13	0.62	-0.24	-0.13	0.15	1.0	-0.02
Ptb Ratio	-0.16		-0.16	-0.04	0.25	-0.16	0.46	-0.69	0.62	1.0	-0.16	0.46	-0.24	0.45	-0.08	-0.23	-0.12	-0.16	-0.8	-0.74	0.0	-0.62	-0.74	0.27	-0.16	-0.24
Days Sales Outstanding	1.0	-0.16		0.06	-0.18	1.0	-0.06	0.02	0.24	-0.16	1.0	-0.06	-0.31	-0.05	-0.43	0.01	-0.37	1.0	0.35	-0.13	0.62	-0.24	-0.13	0.15	1.0	-0.02
Book Value Per Share	0.06	-0.04	0.06		0.52	0.06	0.36	0.18	-0.08	-0.04	0.06	0.36	0.35	0.2	0.3	0.56	0.37	0.06	0.3	0.3	-0.15	0.08	0.3	-0.43	0.06	-0.54
Free Cash Flow Yield	-0.18	0.25	-0.18	0.52		-0.18	0.48	0.04	0.33	0.25	-0.18	0.47	-0.17	0.01	0.24	-0.04	0.27	-0.18	-0.14	-0.21	-0.25	-0.33	-0.21	0.19	-0.18	-0.89
Invested Capital	1.0	-0.16	1.0	0.06	-0.18		-0.06	0.02	0.24	-0.16	1.0	-0.06	-0.31	-0.05	-0.43	0.01	-0.37	1.0	0.35	-0.13	0.62	-0.24	-0.13	0.15	1.0	-0.02
Operating Cash Flow Per Share	-0.06	0.46	-0.06	0.36	0.48	-0.06		-0.62	-0.05	0.46	-0.06	1.0	0.39	0.85	0.38	0.39	0.45	-0.06	-0.14	-0.29	-0.31	0.05	-0.29	-0.4	-0.06	-0.7
Average Payables	0.02	-0.69	0.02	0.18	0.04	0.02	-0.62		-0.33	-0.69	0.02	-0.63	0.06	-0.74	0.2	-0.05	0.16	0.02	0.38	0.47	-0.2	0.32	0.47	-0.03	0.02	0.09
Capex To Depreciation	0.24	0.62	0.24	-0.08	0.33	0.24	-0.05	-0.33		0.62	0.24	-0.06	-0.85	-0.18	-0.52	-0.59	-0.59	0.24	-0.48	-0.56	0.47	-1.0	-0.56	0.84	0.24	-0.16
Pb Ratio	-0.16	1.0	-0.16	-0.04	0.25	-0.16	0.46	-0.69	0.62		-0.16	0.46	-0.24	0.45	-0.08	-0.23	-0.12	-0.16	-0.8	-0.74	0.0	-0.62	-0.74	0.27	-0.16	-0.24
Ev To Sales	1.0	-0.16	1.0	0.06	-0.18	1.0	-0.06	0.02	0.24	-0.16		-0.06	-0.31	-0.05	-0.43	0.01	-0.37	1.0	0.35	-0.13	0.62	-0.24	-0.13	0.15	1.0	-0.02
Free Cash Flow Per Share	-0.06	0.46	-0.06	0.36	0.47	-0.06	1.0	-0.63	-0.06	0.46	-0.06		0.39	0.85	0.38	0.39	0.45	-0.06	-0.14	-0.29	-0.31	0.06	-0.29	-0.4	-0.06	-0.69
Inventory Turnover	-0.31	-0.24	-0.31	0.35	-0.17	-0.31	0.39	0.06	-0.85	-0.24	-0.31	0.39		0.52	0.68	0.68	0.75	-0.31	0.2	0.48	-0.62	0.85	0.48	-0.96	-0.31	-0.04
Net Income Per Share	-0.05	0.45	-0.05	0.2	0.01	-0.05	0.85	-0.74	-0.18	0.45	-0.05	0.85	0.52		0.35	0.47	0.43	-0.05	-0.14	-0.16	-0.26	0.18	-0.16	-0.55	-0.05	-0.24
Days Of Inventory On Hand	-0.43	-0.08	-0.43	0.3	0.24	-0.43	0.38	0.2	-0.52	-0.08	-0.43	0.38	0.68	0.35		0.2	0.87	-0.43	-0.03	0.29	-0.9	0.52	0.29	-0.55	-0.43	-0.25
Payables Turnover	0.01	-0.23	0.01	0.56	-0.04	0.01	0.39	-0.05	-0.59	-0.23	0.01	0.39	0.68	0.47	0.2		0.46	0.01	0.42	0.33	-0.08	0.59	0.33	-0.84	0.01	-0.16
Average Inventory	-0.37	-0.12	-0.37	0.37	0.27	-0.37	0.45	0.16	-0.59	-0.12	-0.37	0.45	0.75	0.43	0.87	0.46		-0.37	0.01	0.33	-0.79	0.59	0.33	-0.69	-0.37	-0.31
Capex To Revenue	1.0	-0.16	1.0	0.06	-0.18	1.0	-0.06	0.02	0.24	-0.16	1.0	-0.06	-0.31	-0.05	-0.43	0.01	-0.37		0.35	-0.13	0.62	-0.24	-0.13	0.15	1.0	-0.02
Cash Per Share	0.35	-0.8	0.35	0.3	-0.14	0.35	-0.14	0.38	-0.48	-0.8	0.35	-0.14	0.2	-0.14	-0.03	0.42	0.01	0.35		0.53	0.2	0.47	0.53	-0.32	0.35	0.06
Pocfratio	-0.13	-0.74	-0.13	0.3	-0.21	-0.13	-0.29	0.47	-0.56	-0.74	-0.13	-0.29	0.48	-0.16	0.29	0.33	0.33	-0.13	0.53		-0.27	0.56	1.0	-0.47	-0.13	0.29
Interest Coverage	0.62	0.0	0.62	-0.15	-0.25	0.62	-0.31	-0.2	0.47	0.0	0.62	-0.31	-0.62	-0.26	-0.9	-0.08	-0.79	0.62	0.2	-0.27		-0.48	-0.27	0.44	0.62	0.18
Capex To Operating Cash Flow	-0.24	-0.62	-0.24	0.08	-0.33	-0.24	0.05	0.32	-1.0	-0.62	-0.24	0.06	0.85	0.18	0.52	0.59	0.59	-0.24	0.47	0.56	-0.48		0.56	-0.83	-0.24	0.16
Pfcf Ratio	-0.13	-0.74	-0.13	0.3	-0.21	-0.13	-0.29	0.47	-0.56	-0.74	-0.13	-0.29	0.48	-0.16	0.29	0.33	0.33	-0.13	0.53	1.0	-0.27	0.56		-0.47	-0.13	0.29
Days Payables Outstanding	0.15	0.27	0.15	-0.43	0.19	0.15	-0.4	-0.03	0.84	0.27	0.15	-0.4	-0.96	-0.55	-0.55	-0.84	-0.69	0.15	-0.32	-0.47	0.44	-0.83	-0.47		0.15	0.04
Net Current Asset Value	1.0	-0.16	1.0	0.06	-0.18	1.0	-0.06	0.02	0.24	-0.16	1.0	-0.06	-0.31	-0.05	-0.43	0.01	-0.37	1.0	0.35	-0.13	0.62	-0.24	-0.13	0.15		-0.02
Income Quality	-0.02	-0.24	-0.02	-0.54	-0.89	-0.02	-0.7	0.09	-0.16	-0.24	-0.02	-0.69	-0.04	-0.24	-0.25	-0.16	-0.31	-0.02	0.06	0.29	0.18	0.16	0.29	0.04	-0.02

Click cells to compare fundamentals

ESSA Pharma Account Relationship Matchups

ESSA Pharma fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	1.95	1.59	0.48	0.94	2.09	52.01
Book Value Per Share	3.53	5.04	3.79	3.3	2.81	2.02
Operating Cash Flow Per Share	(0.76)	(0.66)	(0.65)	(0.45)	(0.51)	(2.62)
Pb Ratio	1.95	1.59	0.48	0.94	2.09	52.01
Free Cash Flow Per Share	(0.76)	(0.66)	(0.65)	(0.45)	(0.51)	(2.62)
Net Income Per Share	(1.04)	(0.96)	(0.8)	(0.6)	(2.38)	(2.5)
Cash Per Share	3.49	5.07	3.8	3.36	2.86	1.07
Pocfratio	(9.12)	(12.11)	(2.79)	(6.89)	(11.81)	(37.26)
Interest Coverage	(37.4)	(1.7K)	(2.5K)	(4.6K)	(5.3K)	(5.1K)
Pfcf Ratio	(9.12)	(12.11)	(2.79)	(6.89)	(11.81)	(37.26)
Income Quality	0.72	0.69	0.82	0.74	0.8	1.24
Roe	(0.21)	(0.3)	(0.19)	(0.18)	(1.71)	(1.62)
Ev To Operating Cash Flow	(5.81)	(6.7)	(0.81)	(5.19)	(7.26)	(36.79)
Pe Ratio	(6.61)	(8.36)	(2.28)	(5.13)	(30.05)	(28.55)
Ev To Free Cash Flow	(5.81)	(6.7)	(0.81)	(5.19)	(7.26)	(36.79)
Earnings Yield	(0.15)	(0.12)	(0.44)	(0.2)	(0.0344)	(0.0362)
Net Debt To E B I T D A	2.45	3.75	1.62	1.27	0.39	0.37
Current Ratio	66.92	50.28	73.38	42.57	38.64	7.06
Tangible Book Value Per Share	3.53	5.04	3.79	3.3	2.81	1.87
Graham Number	9.11	10.42	8.25	6.69	11.86	12.85
Shareholders Equity Per Share	3.53	5.04	3.79	3.3	2.89	2.02
Debt To Equity	0.001706	0.001256	5.52E-4	0.00257	0.002313	0.002429
Graham Net Net	3.43	4.97	5.0	3.28	2.79	1.59
Interest Debt Per Share	0.009178	0.005083	0.001979	0.007436	0.008552	0.008124
Debt To Assets	0.00167	0.001238	5.39E-4	0.00257	0.002956	0.002808
Enterprise Value Over E B I T D A	(4.29)	(4.64)	(0.66)	(3.88)	(30.04)	(28.54)
Roic	(0.29)	(0.19)	(0.21)	(0.22)	(1.34)	(1.4)
Price Earnings Ratio	(6.61)	(8.36)	(2.28)	(5.13)	(30.05)	(28.55)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Inventory Turnover	Net Income Per Share
Days Of Inventory On Hand	Payables Turnover
Sales General And Administrative To Revenue	Average Inventory
Research And Ddevelopement To Revenue	Capex To Revenue
Cash Per Share	Pocfratio
Interest Coverage	Payout Ratio
Capex To Operating Cash Flow	Pfcf Ratio
Days Payables Outstanding	Net Current Asset Value
Income Quality	Roe
Tangible Asset Value	Ev To Operating Cash Flow
Pe Ratio	Return On Tangible Assets
Ev To Free Cash Flow	Earnings Yield
Intangibles To Total Assets	Net Debt To E B I T D A
Current Ratio	Tangible Book Value Per Share
Receivables Turnover	Graham Number
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Roic
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

ESSA Historical Financial Ratios

About ESSA Financial Ratios Analysis

ESSA Pharma Financial Ratios Chart

Price To Sales Ratio

Invested Capital

Average Payables

ESSA Pharma fundamentals Correlations

ESSA Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ESSA Pharma fundamentals Accounts

Also Currently Popular

Additional Tools for ESSA Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Days Sales Outstanding	+ 1.0	Price To Sales Ratio
Invested Capital	+ 1.0	Price To Sales Ratio
Ev To Sales	+ 1.0	Price To Sales Ratio
Capex To Revenue	+ 1.0	Price To Sales Ratio
Net Current Asset Value	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio

Capex To Operating Cash Flow	- 1.0	Capex To Depreciation
Days Payables Outstanding	- 0.96	Inventory Turnover
Interest Coverage	- 0.9	Days Of Inventory On Hand
Income Quality	- 0.89	Free Cash Flow Yield
Inventory Turnover	- 0.85	Capex To Depreciation
Days Payables Outstanding	- 0.84	Payables Turnover